Precigen (PGEN) Long-Term Investments (2012 - 2026)
Precigen (PGEN) posted quarterly Long-Term Investments of $489000.0 for Q1 2026, down 34.8% year-over-year from $750000.0 in Q1 2025, and down 80.53% quarter-over-quarter from $2.5 million in Q4 2025.
Analysis
Precigen (PGEN) Long-Term Investments (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Long-Term Investments for 14 consecutive years, with $489000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 34.8% year-over-year to $489000.0; the TTM figure through Mar 2026 stood at $489000.0 (down 34.8% YoY), while the FY2025 annual figure was $2.5 million, changed N/A from the prior year.
- Long-Term Investments declined to $489000.0 in Q1 2026 per PGEN's latest filing, from $2.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $29.9 million in Q1 2022 and bottomed at $489000.0 in Q1 2026.
- Historically, Long-Term Investments has averaged $7.5 million across 4 years, with a median of $5.3 million in 2023.
- Annual changes were most pronounced in 2022 — Long-Term Investments sank 86.07% — and 2026, when it sank 34.8%.
- Precigen's Long-Term Investments stood at $11.9 million in 2022, then slumped by 55.62% to $5.3 million in 2023, then slumped by 52.36% to $2.5 million in 2025, then tumbled by 80.53% to $489000.0 in 2026.
- Business Quant data shows PGEN's Long-Term Investments at $489000.0 in Q1 2026, $2.5 million in Q4 2025, and $2.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 490,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 490,000.00 |
| Mar 31, 2026 | 489,000.00 |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 750,000.00 |
| Sep 30, 2023 | 5.27 Mn |
| Jun 30, 2023 | 7.13 Mn |
| Mar 31, 2023 | 7.46 Mn |
| Jun 30, 2022 | 11.88 Mn |
| Mar 31, 2022 | 29.91 Mn |
| Dec 31, 2021 | 48.56 Mn |
| Sep 30, 2021 | 66.93 Mn |
| Jun 30, 2021 | 85.27 Mn |
| Mar 31, 2021 | 103.61 Mn |
| Sep 30, 2020 | 337,000.00 |
| Jun 30, 2020 | 859,000.00 |
| Mar 31, 2020 | 1.11 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Sep 30, 2019 | 17.49 Mn |
| Jun 30, 2019 | 21.50 Mn |